CancerNext®
Use
CancerNext is a guideline-based test option from Ambry Genetics, including genes with clinical management recommendations for hereditary cancer predisposition. It focuses on various cancer syndromes like breast, ovarian, pancreatic, prostate, colorectal, endometrial, gastric, small bowel, urothelial, and renal cancers. Testing may inform cancer risk management, treatment options, and medical management of family members.
Special Instructions
The test is intended for epithelial ovarian cancers only. Non-epithelial ovarian cancer genes are not specifically targeted. Family variant testing is available at no additional cost, for first-degree relatives within 90 days post-initial test result.
Limitations
Variants in regions complicated by pseudogene interference or low variant allele frequency may require Sanger verification. Intronic variants beyond 5bp from splice junctions that are of uncertain significance are not reported. Detection of some large deletions or duplications may be limited in certain genes.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Container
Unknown at time of extraction
Collection Instructions
Consult specimen requirements at ambrygen.com.
Causes for Rejection
Blood/saliva from patients with bone marrow or stem cell transplant history not recommended.